Common Research Facilities
Contact
Medical Institute of Bioregulation, Kyushu University
3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, JAPAN
TEL +81-92-642-6814
FAX +81-92-642-6246

Mission of the Institute

所長

Director Yoshinori Fukui

April 1st, 2023


The Medical Institute of Bioregulation, Kyushu University focuses on the host-defense system, and pursues its regulatory mechanisms at the molecular, cellular and individual levels to better understand the human biology and the disease pathogenesis. With outstanding research achievement, our institute has become one of the most active and productive research institutes in Japan. By further facilitating the fusion of technology and biology, we currently aim at developing a center of excellence to promote the advanced host-defense research in multiple scales and from diverse directions.

The Medical Institute of Bioregulation was founded in April 1982, through combination of the Research Institute of Balneotherapeutics in Beppu and the Cancer Research Center in Fukuoka. In April 2001, to better serve the above aims in this rapidly changing era, the institute was largely reorganized into three departments (the Department of Molecular Genetics, the Department of Molecular and Cellular Biology, and the Department of Immunobiology and Neuroscience) with 12 divisions and two research centers (the Research Center for Genetic Information and the Research Center for Prevention of Infectious Diseases) with 8 divisions. In April 2009 and April 2010, respectively, two new research centers, the Research Center for Infectious Diseases and the Multi-scale Research Center for Medical Science were established. Since April 2010, our Institute was authorized as a Joint Usage/Research Center for the Multi-stratified Host Defense System by the Ministry of Education, Culture, Sports, Science and Technology, Japan; this promoted domestic and international joint research on the host-defense system. In April 2011, the existing clinical divisions and hospital in Beppu joined the Kyushu University Hospital, thus enabling our institute to concentrate on further advancements in basic medical research.

In April 2013, the Research Center for Genetic Information was reorganized as the Research Center for Transomics Medicine, which has promoted basic medical research using transomics approaches. Based on this achievement, we have developed Medical Research Center for High Depth Omics in 2022. In this center, tightly collaborating with three other Joint Usage/Research Centers in Japan, we aim at elucidating the mechanisms of human diseases such as infectious diseases, allergy and cancers through acquisition and analyses of big data with high precision and high resolution. For this purpose, we have recruited 4 professors. In addition, following our third approval as a Joint Usage/Research Center for the Multi-stratified Host Defense System (2022–2027), our state-of-the-art facilities provide researchers worldwide with various services, including high-throughput DNA sequencing, electron microscopic analysis, NMR analysis, proteomic/metabolomic analyses, transgenic animal production, and more.

In April 2018, the Research Center for Infectious Diseases and the Multi-scale Research Center for Medical Science have been combined to establish the Research Center for Systems Immunology. The three departments have also been reorganized as the Department of Molecular and Structural Biology, the Department of Molecular and Cellular Biology, and the Department of Immunobiology and Neuroscience. Last year, we have recruited 2 professors who belong to either of the three department. On the other hand, our faculty members will continue to contribute to the education of the Graduate School of Medical Sciences and the Graduate School of Systems Life Sciences of Kyushu University.

Thus, the organization of our institute has largely changed in 2022 to facilitate advanced studies of the host-defense system via high depth omics approach. We sincerely hope that our research activity will enhance the understanding of complex pathological processes and facilitate the development of therapies to cure intractable diseases. We greatly appreciate your support and cooperation as we move forward.